Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
暂无分享,去创建一个
A. Okamoto | T. Kasamatsu | K. Ushijima | H. Yoshikawa | T. Onda | N. Yaegashi | M. Takano | K. Kawana | K. Takehara | Toshiaki Saito | T. Kamura | H. Kanao | T. Nakanishi | Yoh Watanabe | G. Ogawa | T. Mizutani | Hiroaki Kobayashi | T. Satoh | Kaichiro Yamamoto | H. Yokota | T. Saito
[1] M. Parmar,et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. , 2018, The Lancet. Oncology.
[2] J. Griggs,et al. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Schorge,et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. , 2016, Gynecologic oncology.
[4] I. Vergote,et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Gynecologic oncology.
[5] I. Vergote,et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Kasamatsu,et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. , 2016, European journal of cancer.
[7] G. Scambia,et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. , 2016, European journal of cancer.
[8] P. Lumbiganon,et al. Interval debulking surgery for advanced epithelial ovarian cancer. , 2016, The Cochrane database of systematic reviews.
[9] H. Kitchener,et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.
[10] G. Baiocchi,et al. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer , 2015, Annals of Surgical Oncology.
[11] H. Hricak,et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. , 2014, Gynecologic oncology.
[12] G. Scambia,et al. Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy , 2013, Annals of Surgical Oncology.
[13] R. Berkowitz,et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. , 2013, Gynecologic oncology.
[14] Herbert Yu,et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV) , 2013, Journal of surgical oncology.
[15] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[16] M. Hatae,et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. , 2009, Gynecologic oncology.
[17] J. McAlpine,et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. , 2007, Gynecologic oncology.
[18] A. Jazaeri,et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. , 2006, American journal of obstetrics and gynecology.
[19] S. Rubin,et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.
[20] Hys Ngan,et al. Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[21] G. Tulunay,et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma , 2001, International Journal of Gynecologic Cancer.
[22] C. Pomel,et al. Cytoreductive surgery for advanced stages of ovarian cancer. , 2000, Seminars in surgical oncology.
[23] M. Buyse,et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.
[24] J. Wharton,et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. , 1991, Gynecologic oncology.
[25] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[26] D. Chi,et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. , 2011, Gynecologic oncology.
[27] P. Lumbiganon,et al. Interval debulking surgery for advanced epithelial ovarian cancer. , 2010, The Cochrane database of systematic reviews.
[28] A. Sato,et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. , 2008, Japanese journal of clinical oncology.
[29] D. Atallah,et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] S. Rakar,et al. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. , 2002, European journal of gynaecological oncology.
[31] P. Schwartz,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.